GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Even following the adoption of measures such as the White Australia Policy and the Chinese Exclusion Act in English-speaking settler colonies, pervasive control of international borders remained a relatively rare phenomenon until the early 20th century, before which many states had open international borders either in practice or due to a lack of any legal restriction. John Maynard Keynes identified World War I in particular as the point when such controls became commonplace. Decolonisation during the twentieth century saw the emergence of mass emigration from nations in the Global South, thus leading former colonial occupiers to introduce stricter border controls. In the United Kingdom this process took place in stages, with British nationality law eventually shifting from recognising all Commonwealth citizens as British subjects to today's complex British nationality law which distinguishes between British citizens, modern British Subjects, British Overseas Citizens, and overseas nationals, with each non-standard category created as a result of attempts to balance border control and the need to mitigate statelessness. This aspect of the rise of border control in the 20th century has proven controversial. The British Nationality Act 1981 has been criticised by experts, as well as by the Committee on the Elimination of Racial Discrimination of the United Nations, on the grounds that the different classes of British nationality it created are, in fact, closely related to the ethnic origins of their holders.
nonsense suppressor A factor which can inhibit the effects of a nonsense mutation (i.e. a premature stop codon) by any mechanism, usually either a mutated transfer RNA which can bind the mutated stop codon or some kind of ribosomal mutation.
=== Aspirational use as green chemicals === Natural polyphenols have long been proposed as renewable precursors to produce plastics or resins by polymerization with formaldehyde, as well as adhesives for particleboards. The aims are generally to make use of plant residues from grape, olive (called pomaces), or pecan shells left after processing.
Sources: en.wikipedia.org
=== Anaplasia === Anaplasia is defined as cells being in an undifferentiated state and it is often associated with cancer. Often this loss of mature cell markers or morphology can be due to dedifferentiation, but it is sometimes used to refer to cells with incomplete differentiation presenting large variety in size and shape. While its definition can be conflated with dedifferentiation, it is more often perceived as a loss of differentiation leading to abnormal cell activity, including but not limited to tumorigenesis. However, dedifferentiation is often perceived as a reversion to a different cell type for regenerative purposes. In anaplastic cells, there is often an increase in proliferation and abnormal cellular organization, characteristics that are also present in dedifferentiated cells.
=== February === 1 February – An estimated 475,000 workers go on strike, the single biggest day of industrial action for more than a decade, in disputes over pay and conditions. This includes 200,000 teachers, 100,000 civil servants including border force workers, university lecturers, security guards, and train drivers. The government warns the public to expect "significant disruption". 2 February The Bank of England raises its key interest rate from 3.5 to 4%, the highest level in 14 years. The energy regulator Ofgem asks energy companies to suspend the forced installation of prepayment meters following an investigation by The Times which showed agents working for British Gas breaking into the homes of vulnerable customers to install the meters. 3 February Gary Glitter is freed from prison after serving half of a 16-year jail term for attempted rape, four counts of indecent assault and one of having sex with a girl under 13. COVID-19 in the UK: Office for National Statistics data for the week up to 24 January indicates that COVID-19 cases continue to fall, with an estimated 1 in 70 people (1.42% of the population) testing positive for the virus in England over that time. 5 February Emma Pattinson, the head of Epsom College in Surrey, is found dead along with her husband and seven-year-old daughter in a property at the school. Police suspect a murder-suicide by gunshot.
The Edman degradation is a very important reaction for protein sequencing, because it allows the ordered amino acid composition of a protein to be discovered. Automated Edman sequencers are now in widespread use, and are able to sequence peptides up to approximately 50 amino acids long. A reaction scheme for sequencing a protein by the Edman degradation follows; some of the steps are elaborated on subsequently.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.